Delgado-Ortiz L, Carsin AE, Merino J, Cobo I, Koch S, Goldberg X, Chevance G, Bosch de Basea M, Castano-Vinyals G, Espinosa A, Carreras A, Cortes Martinez B, Straif K, de Cid R, Kogevinas M, Garcia-Aymerich J. Changes in population health-related behaviors during a COVID-19 surge: a natural experiment. Ann Behav Med. 2023 Apr 5;57(3):216-26. doi: 10.1093/abm/kaac054
Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603
Launois R, Fiestas Navarette L, Ethgen O, Le Moine J, Gatsinga R. Health economic value of an innovation: delimiting the scope and framework of future market entry agreements. J Market Access Health Policy. 2014 Jun;2:24988. doi: 10.3402/jmahp.v2.24988
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
King TK, Britt DM, Day A. Changes in body esteem and sexual satisfaction in obese females enrolled in a weight loss program. Ann Behav Med. 2001;23(Suppl):S023.
King TK, Britt DM, Lloyd E. Demographic and psychological characteristics of obese smokers presenting for weight loss treatment. Ann Behav Med. 2001;23(Suppl):S027.
Britt (DiBenedetti) DM, Seaton M, Cohan LM, Collins FL. Cigarette smoking and chewing gum: response to a laboratory-induced stressor. Poster presented at the Association for the Behavioral Sciences and Medical Education Conference; 1999. [abstract] Ann Behav Med. 1999; 21(Suppl):S039.
Cohen LM, Britt (DiBenedetti) DM, Collins FL, al’Absi M. A multimodal assessment of the effect of chewing gum on tobacco withdrawal. Poster presented at the Association for the Behavioral Sciences and Medical Education Conference; 1999. [abstract] Ann Behav Med. 1999; 21(Suppl):S039.
Stetson B, Dubbert P, Rahn J, Wilner B, Mercury M, Britt (DiBenedetti) D. Gender differences in the cognitive appraisal of exercise relapse. Poster presented at the 1993 Society of Behavioral Medicine Conference; 1993. [abstract] Ann Behav Med. 1993 Jun 1; 15(2-3):S167. doi: 10.1093/abm/15.2-3.164
Stetson B, Dubbert P, Wilner B, Rahn J, Mercury M, Britt (DiBenedetti) D. Influence of biological and psychosocial factors on activity in free-exercising adults. Poster presented at the 1993 Society of Behavioral Medicine Conference; 1993. [abstract] Ann Behav Med. 1993; 15(Suppl):S167.
Smith PO, Stetson B, Dubbert P, Mercury M, Rahn J, Britt (DiBenedetti) DM. Body image differences in adult exercising women. Poster presented at the 1993 Society of Behavioral Medicine Conference; 1993. [abstract] Ann Behav Med. 1993; 15(Suppl):S167.